TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37409467

Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 h/night)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sleep restriction (-1.5 h/night)
Number of subjects: 65
Study: 37409509

Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate
Number of subjects: 106
Study: 37409565

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade for 3 months
Number of subjects: 34
Study: 37409613

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy (monotherapy or combined with chemotherapy)
Number of subjects: 106
Study: 37409664

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) left ventricular assist device (LVAD)
Number of subjects: 43
Study: 37409757

Group type: EXPERIMENTAL
Intervention: Betaine supplementation (2.5 and 5.0 g/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no betaine supplementation)
Number of subjects: 43
Study: 37409780

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 25
Study: 37409817

Group type: EXPERIMENTAL
Intervention: ICP-based management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ICP-based management
Number of subjects: 0
Study: 37409892

Group type: EXPERIMENTAL
Intervention: Non-invasive prenatal testing (NIPT) results suggesting maternal cancer
Number of subjects: 49
Study: 37409991

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI
Number of subjects: 1237
Study: 37409992

Group type: EXPERIMENTAL
Intervention: Adjunctive Transcoronary Pacing Strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rotational Atherectomy
Number of subjects: 0
Study: 37410050

Group type: EXPERIMENTAL
Intervention: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) cream
Number of subjects: 784

Group type: COMPARATOR
Intervention: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) topical solution
Number of subjects: 784

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 784
Study: 37410417

Group type: EXPERIMENTAL
Intervention: Psychiatric service dog placement
Number of subjects: 168
Study: 37410421

Group type: EXPERIMENTAL
Intervention: Mindfulness training for primary care (MTPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose mindfulness comparator (LDC)
Number of subjects: 0
Study: 37410465

Group type: EXPERIMENTAL
Intervention: Risk-stratified care (physiotherapy treatment tailored for risk category)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Risk-stratified care
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care (determined by general practitioners)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study: 37410476

Group type: COMPARATOR
Intervention: Anti-PD-1/PD-1 ligand 1 ICIs alone (control arm)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-1 ligand 1 ICIs combined with stereotactic body radiotherapy (experimental arm)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 99
Study: 37410518

Group type: EXPERIMENTAL
Intervention: COM-B questionnaire
Number of subjects: 0
Study: 37410541

Group type: EXPERIMENTAL
Intervention: Blood Cancer Coach app intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attention control (Springboard Beyond Cancer website)
Number of subjects: 180
Study: 37410699

Group type: EXPERIMENTAL
Intervention: Catch-up HPV test (intervention group)
Number of subjects: 11212

Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 11212
Study: 37410740

Group type: EXPERIMENTAL
Intervention: Medication purchased in the informal sector
Number of subjects: 439

Group type: COMPARATOR
Intervention: Medication purchased in the formal sector
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Antibiotic usage in the informal sector
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Distance from the closest study site
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Community cohort site inclusion
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Illness with general malaise, fever, or headache
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Wound/skin disease
Number of subjects: 439
Study: 37411031

Group type: EXPERIMENTAL
Intervention: Subsequent immunotherapy
Number of subjects: 15
Study: 37411039

Group type: EXPERIMENTAL
Intervention: Icenticaftor, a CFTR potentiator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37413896

Group type: EXPERIMENTAL
Intervention: Culturally adapted Positive Health Programme (PHP) (n = 42)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 41)
Number of subjects: 83
Study: 37413939

Group type: EXPERIMENTAL
Intervention: Group 1 (COVID-19 outpatients)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Group 2 (hospitalized COVID-19 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Group 3 (control group without COVID-19)
Number of subjects: 29
Study: 37414012

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with BCMA CAR T cells
Number of subjects: 19
Study: 37414060

Group type: EXPERIMENTAL
Intervention: ARI0002h (BCMA-directed CAR T-cell therapy)
Number of subjects: 35
Study: 37414062

Group type: EXPERIMENTAL
Intervention: Sorafenib maintenance (400 mg orally twice daily)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Non-maintenance (control)
Number of subjects: 202
Study: 37414064

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA bifrontal stimulation for 30 min every weekday for 4 weeks, then two sessions per week for 2 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham tDCS (same intervals as active tDCS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 150
Study: 37414066

Group type: EXPERIMENTAL
Intervention: Cabamiquine 60 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine 80 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine 100 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine 200 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine 30 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pooled placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine 30 mg, 60 mg, 80 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabamiquine (all doses)
Number of subjects: 39
Study: 37414069

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 1678
Study: 37414071

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 109
Study: 37414137

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitor (TNFi)
Number of subjects: 626

Group type: COMPARATOR
Intervention: NSAID use
Number of subjects: 626
Study: 37414215

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab 200 mg IV followed by 1 year of adjuvant pembrolizumab
Number of subjects: 30
Study: 37414422

Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 79
Study: 37414440

Group type: EXPERIMENTAL
Intervention: Endoscopic retreatment using hot snare resection, cold avulsion forceps with adjuvant snare tip soft coagulation, or a combination of the two.
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy of recurrence
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of RRA
Number of subjects: 213
Study: 37414460

Group type: COMPARATOR
Intervention: PA (Patient advice)
Number of subjects: 180

Group type: COMPARATOR
Intervention: PAX (Patient advice plus exercise)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PAXI (Patient advice plus exercise plus corticosteroid injection)
Number of subjects: 180
Study: 37414613

Group type: EXPERIMENTAL
Intervention: Oblique technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: AP technique
Number of subjects: 200
Study: 37414702

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography (PET/CT) with 296 MBq injection
Number of subjects: 352
Study: 37414705

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine-cisplatin (GC)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Pathologic response (<pT2)
Number of subjects: 227
Study: 37414899

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) plus PD-1 inhibitors (nivolumab or pembrolizumab)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (FMT plus PD-1 inhibitors)
Number of subjects: 20
Study: 37414923

Group type: EXPERIMENTAL
Intervention: Tenofovir-based antiretroviral therapy (tenofovir, lamivudine, efavirenz)
Number of subjects: 1288
Study: 37415001

Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg once daily orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (7.5 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran etexilate (75 mg orally)
Number of subjects: 0
Study: 37415024

Group type: EXPERIMENTAL
Intervention: Continuous and Remote Early Warning Score-based notification protocol (CREWS)
Number of subjects: 102
Study: 37415048

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) using an inspiratory threshold loading device at 4 cmH2O
Number of subjects: 26
Study: 37415100

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Surgery (11 as primary treatment and 4 during follow-up)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection or platelet rich plasma injection
Number of subjects: 97
Study: 37415099

Group type: EXPERIMENTAL
Intervention: REDCap automated double randomization
Number of subjects: 0
Study: 37415221

Group type: EXPERIMENTAL
Intervention: Superficial parasternal intercostal plane block (SPIP) with standard care
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Deep parasternal intercostal plane block (DPIP) with standard care
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard care without regional anesthesia (Control)
Number of subjects: 254
Study: 37415223

Group type: EXPERIMENTAL
Intervention: Plasma protein biomarkers in cases (patients who developed pneumonia)
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Plasma protein biomarkers in controls (patients who did not develop pneumonia)
Number of subjects: 1997
Study: 37415239

Group type: EXPERIMENTAL
Intervention: DZD1516 monotherapy at 250 mg, twice daily (BID)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DZD1516 monotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DZD1516
Number of subjects: 23
Study: 37415246

Group type: EXPERIMENTAL
Intervention: Adjunctive lifestyle intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 37415381

Group type: EXPERIMENTAL
Intervention: Echocardiographic stroke work (SW) using integrated pressure-strain myocardial work (MW) software
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Echocardiographic wasted work (RVGWW)
Number of subjects: 42
Study: 37415503

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tirzepatide
Number of subjects: 0
Study: 37415648

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combined Therapy (CT) - oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combined Therapy (CT)
Number of subjects: 90
Study: 37415687

Group type: EXPERIMENTAL
Intervention: Male-specific psychotherapeutic program (MSPP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 144
Study: 37415712

Group type: EXPERIMENTAL
Intervention: Paro robot integrated with usual care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional therapy (cognitive stimulation and occupational activities)
Number of subjects: 20
Study: 37415845

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 18
Study: 37415957

Group type: EXPERIMENTAL
Intervention: Before enzyme replacement therapy
Number of subjects: 20
Study: 37416926

Group type: EXPERIMENTAL
Intervention: mRNA SARS-CoV-2 vaccination-related myocarditis
Number of subjects: 59
Study: 37417229

Group type: EXPERIMENTAL
Intervention: Self-expanding ACURATE neo (NEO)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Balloon-expandable SAPIEN 3 (S3)
Number of subjects: 739
Study: 37417239

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 1 pass
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 2 passes
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 3 to 7 passes
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with failed reperfusion
Number of subjects: 202

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 202
Study: 37417601

Group type: EXPERIMENTAL
Intervention: Modified star-shaped incision on gingival sulcus before zirconia crown placement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified star-shaped incision
Number of subjects: 24
Study: 37417619

Group type: EXPERIMENTAL
Intervention: Dialyzable leukocyte extract (DLE) administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks.
Number of subjects: 30
Study: 37417631

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myofascial release technique (MRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37417650

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) to egg white (EW)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) to EW
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT) to egg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT) to egg in children younger than 2 years
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BAT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: sIgE followed by BAT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Using 100% sensitivity and 100% specificity cut-offs followed by OFC
Number of subjects: 150

Group type: COMPARATOR
Intervention: DBPCFC to baked egg (BE)
Number of subjects: 150

Group type: COMPARATOR
Intervention: DBPCFC to lightly cooked egg (LCE)
Number of subjects: 150
Study: 37417725

Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Number of subjects: 511

Group type: COMPARATOR
Intervention: abaloparatide-SC
Number of subjects: 511
Study: 37417781

Group type: EXPERIMENTAL
Intervention: Tezepelumab plus standard of care (SoC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 0
Study: 37417824

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors
Number of subjects: 5050

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5050

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 5050

Group type: EXPERIMENTAL
Intervention: Triple therapy (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin receptor-neprilysin inhibitors+beta-blocker+mineralocorticoid receptor antagonist)
Number of subjects: 5050
Study: 37417948

Group type: EXPERIMENTAL
Intervention: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, tumor bed, and residual contrast enhancements, with concomitant Temozolomide for 6 months.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard dose (SD) of 60 Gy with concomitant Temozolomide for 6 months.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard dose (SD) of 60 Gy.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High dose (HD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard dose (SD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Number of subjects: 180
Study: 37417970

Group type: EXPERIMENTAL
Intervention: Submucosal Platelet-Rich Plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Platelet-Rich Plasma Noncrosslinked Hyaluronic Acid Injections
Number of subjects: 0
Study: 37418031

Group type: EXPERIMENTAL
Intervention: Trilaciclib plus gemcitabine plus carboplatin (GCb)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GCb) alone
Number of subjects: 102
Study: 37418059

Group type: EXPERIMENTAL
Intervention: Personal Analgesic Sufficiency Status (PASS) measured by pre-tetanus-induced ANI variation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane and increased effect-site concentrations of remifentanil (2, 4, 6 ng/ml)
Number of subjects: 0
Study: 37418060

Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard mask ventilation
Number of subjects: 0
Study: 37418263

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment (1000 U/kg/dose on days 1, 2, 3, 4, and 7)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 500
Study: 37418303

Group type: EXPERIMENTAL
Intervention: COMET-SSI (n=409)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Waiting list control (n=419)
Number of subjects: 828
Study: 37418304

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention leveraging EHR-based data and team-based care
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 10
Study: 37418363

Group type: EXPERIMENTAL
Intervention: Go NAPSACC+ Staff Wellness
Number of subjects: 168

Group type: COMPARATOR
Intervention: Go NAPSACC
Number of subjects: 168
Study: 37418498

Group type: EXPERIMENTAL
Intervention: iCARE Nigeria HIV treatment support intervention (peer navigation and SMS text message medication reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 0
Study: 37418583

Group type: EXPERIMENTAL
Intervention: Mixture of injectable-platelet-rich fibrin (i-PRF) and type-1 collagen particles applied to the defect in adjunct to periapical surgery (n=19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No guided bone regeneration procedures (Control group, n=19)
Number of subjects: 38
Study: 37418643

Group type: EXPERIMENTAL
Intervention: EYS C2139Y variant (6416G>A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: EYS C2139Y-related RP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Carrier prevalence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Targeted molecular therapy
Number of subjects: 150
Study: 37418685

Group type: EXPERIMENTAL
Intervention: Rituximab and lenalidomide (R2) combination therapy: 20 mg oral lenalidomide from days 2 to 22 and IV rituximab 375 mg/m2 on day 1 for a maximum of 6 cycles.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of lenalidomide at 10 mg/d from days 1 to 21 for every 28 days for a total of 12 cycles after achieving partial or complete response.
Number of subjects: 0
Study: 37418844

Group type: EXPERIMENTAL
Intervention: 450 kcal mixed meal tolerance test (MMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 600 kcal high-fat MMT
Number of subjects: 32

Group type: COMPARATOR
Intervention: isocaloric high-carbohydrate MMT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-fat MMT
Number of subjects: 32
Study: 37419055

Group type: EXPERIMENTAL
Intervention: cNSLBP participants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Asymptomatic adults (AA)
Number of subjects: 30
Study: 37419129

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 12 μg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 48 μg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 90 μg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 12 μg
Number of subjects: 179
Study: 37419144

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) 590 mg added to background multidrug therapy for 12 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) 590 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) with clofazimine or clofazimine plus azithromycin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS)
Number of subjects: 33
Study: 37419394

Group type: EXPERIMENTAL
Intervention: 2STAR trial (26 Gy to prostate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2SMART trial (26 Gy to prostate + up to 32 Gy boost to DIL)
Number of subjects: 60
Study: 37419632

Group type: EXPERIMENTAL
Intervention: EMONO+Audiovisual
Number of subjects: 120

Group type: COMPARATOR
Intervention: EMONO alone
Number of subjects: 120
Study: 37419633

Group type: EXPERIMENTAL
Intervention: dyadic expressive arts-based intervention (EXAT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: treatment-as-usual waitlist control group
Number of subjects: 154
Study: 37419639

Group type: EXPERIMENTAL
Intervention: Liberal ultrafiltration (UF)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Restrictive ultrafiltration (UF)
Number of subjects: 112